Abiopharma

Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

NuCana Appoints Theresa Bruce as Chief Operating Officer

Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Johns Hopkins Medicine Treats First Commercial TULSA-PRO® Case

(63% Neutral) REPLIGEN CORP (RGEN) Files Form 8-K

(75% Positive) KALA BIO, Inc. (KALA) Files Form 8-K

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

PMGC Holdings Inc. Announces Strategic Share Acquisition in Micro Modular Reactor (MMR) Focused Nuclear Energy Company, Nuclea Energy Inc.

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program

Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast